Surrozen (SRZN) Research & Development (2020 - 2026)
Surrozen (SRZN) recorded quarterly Research & Development of $9.3 million in Q1 2026, up 3.75% quarter-over-quarter from $9.0 million in Q4 2025, and up 42.24% on a YoY basis from $6.6 million in Q1 2025.
Surrozen (SRZN) Research & Development (2020 - 2026) Analysis & Trends
Surrozen's Research & Development history runs 7 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- In Q1 2026, Research & Development rose 42.24% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $32.1 million (up 43.18% YoY), while the FY2025 annual figure was $29.4 million, up 38.96% from the prior year.
- Research & Development was $9.3 million for Q1 2026 at Surrozen, up from $9.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $9.6 million in Q2 2022 to a low of $5.2 million in Q3 2024.
- Historically, Research & Development has averaged $7.3 million across 5 years, with a median of $6.9 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Research & Development plunged 82.75% in 2022, then surged 68.06% in 2025.
- A 5-year view of Research & Development shows it stood at $9.4 million in 2022, then slumped by 35.41% to $6.1 million in 2023, then decreased by 12.22% to $5.4 million in 2024, then soared by 68.06% to $9.0 million in 2025, then rose by 3.75% to $9.3 million in 2026.
- The last three Research & Development figures came in at $9.3 million (Q1 2026), $9.0 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -58.00 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 9.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.33 Mn |
| Dec 31, 2025 | 8.99 Mn |
| Sep 30, 2025 | 7.77 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Mar 31, 2025 | 6.56 Mn |
| Dec 31, 2024 | 5.35 Mn |
| Sep 30, 2024 | 5.20 Mn |
| Jun 30, 2024 | 5.34 Mn |
| Mar 31, 2024 | 5.25 Mn |
| Dec 31, 2023 | 6.10 Mn |
| Sep 30, 2023 | 6.11 Mn |
| Jun 30, 2023 | 6.94 Mn |
| Mar 31, 2023 | 8.09 Mn |
| Dec 31, 2022 | 9.44 Mn |
| Sep 30, 2022 | 8.62 Mn |
| Jun 30, 2022 | 9.58 Mn |
| Mar 31, 2022 | 9.37 Mn |
| Dec 31, 2021 | 10.89 Mn |
| Sep 30, 2021 | 50.00 Mn |
| Jun 30, 2021 | 10.27 Mn |